Sotera Health Acquires Canadian-based Iotron Industries

Canadian-based Iotron Industries has been acquired by Sotera Health, the world’s leading, fully-integrated protector of global health. The news was announced today (August 3, 2020).

The acquisition expands the company’s electron beam (EBeam) footprint and adds new expertise to its Sterigenics business. Iotron Industries is a leading outsourced provider of EBeam sterilization in North America.

With facilities in Columbia City (Indiana), Port Coquitlam (British Columbia), and Edmonton (Alberta), Iotron Industries has an outstanding reputation for customer service, technical expertise and quality performance. Iotron is well regarded for its proprietary IMPELA® accelerators, which provide high powered EBeam processing for the sterilization of medical devices and a wide range of industrial applications.

“Iotron Industries is a well-respected provider of electron beam sterilization known for its strong customer relationships and the expertise of its employees,” said Michael B. Petras Jr., CEO of Sotera Health. “While this acquisition expands our overall sterilization footprint, it also enhances our EBeam capabilities and the strength of our offering to the market. We welcome Iotron’s management and strong team as they join our mission of Safeguarding Global Health®.”

“I am exceedingly proud of the thriving business and expert team that we have built together at Iotron, and we all look forward to accelerating our growth as part of a global leader,” said Tino Pereira, President and CEO of Iotron Industries. “Iotron and Sotera Health share common values around safety, customer focus, integrity, people and a commitment to excellence. We look forward to a brighter future together.”

The addition of Iotron will complement Sotera Health’s Sterigenics business and enhance Sterigenics’ existing global, technology-agnostic sterilization platform.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version